The goal of this observational study is to evaluate whether perioperative hyperoxia (FiO₂ \> 0.8), compared to conventional oxygen therapy (FiO₂ \< 0.4), is associated with increased cancer recurrence and mortality in patients undergoing curative elective colorectal cancer surgery.
In 2016, the World Health Organization (WHO) recommended the use of perioperative hyperoxia (FiO₂ \> 0.8) to reduce the risk of postoperative surgical site infections (SSIs). However, the WHO also highlighted potential adverse effects associated with hyperoxia, including increased cancer recurrence and mortality. This study aims to evaluate whether perioperative hyperoxia (FiO₂ \> 0.8), compared to conventional oxygen therapy (FiO₂ \< 0.4), is associated with increased cancer recurrence and mortality in patients undergoing curative elective colorectal cancer surgery. This study is a follow-up of a previously published cohort originally designed to assess whether FiO₂ \> 0.8 was associated with a higher incidence of perioperative cardiovascular complications. In this follow-up, oncological recurrence and mortality events were recorded at least three years after the index surgery. The primary outcome was recurrence-free survival over the follow-up period, analyzed using Kaplan-Meier curves and a Cox proportional hazards model. The secondary outcome was the 3-year mortality rate, analyzed using the Chi-square test.
Study Type
OBSERVATIONAL
Enrollment
403
Hospital del Mar
Barcelona, Catalonia, Spain
Recurrence-free Survival
Length of time from the end of primary treatment (surgery in this case) until the evidence of cancer recurrence (locoregional or systemic) or death in the last follow-up
Time frame: Follow-up period (at least 3 years since surgery)
Mortality
Percentage of global mortality (not exclusively related to the oncologic disease)
Time frame: 3-year follow-up period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.